Similar articles

• Finasteride in benign prostatic hyperplasia.

  Verhamme KM, Bosch RJ, Sturkenboom MC. Verhamme KM, et al. N Engl J Med. 2004 Mar 25;350(13):1359-61; author reply 1359-61. N Engl J Med. 2004. PMID: 15049034 No abstract available.
• The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.

  McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, Albertsen P, Roehrborn CG, Nickel JC, Wang DZ, Taylor AM, Waldstreicher J. McConnell JD, et al. N Engl J Med. 1998 Feb 26;338(9):557-63. doi: 10.1056/NEJM199802263380901. N Engl J Med. 1998. PMID: 9475762 Clinical Trial.
• Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or =65 years.

  Fenter TC, Davis EA, Shah MB, Lin PJ. Fenter TC, et al. Am J Manag Care. 2008 May;14(5 Suppl 2):S154-9. Am J Manag Care. 2008. PMID: 18611089
• [The effect of 5-alpha-reductase inhibitors on benign prostatic hyperplasia].

  Djavan B, McConnell J. Djavan B, et al. Wien Med Wochenschr. 1996;146(8):165-8. Wien Med Wochenschr. 1996. PMID: 8767401 Review. German.
• Benign prostatic hyperplasia--review of treatment options.

  Oehlke KJ, Branaugh ML. Oehlke KJ, et al. S D Med. 2009 May;62(5):202-3. S D Med. 2009. PMID: 19489345 Review. No abstract available.